United Guardian (UG) Cash from Operations Growth (3y) (2013 - 2026)
Powered by 
Analysis
United Guardian (UG) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.97 Bn | 622.21 Bn | 17.26 Bn | 27.24% |
| 2 | AbbVie | 441.24 Bn | 434.67 Bn | 12.70 Bn | -18.38% |
| 3 | Merck | 364.65 Bn | 357.51 Bn | 12.21 Bn | 13.18% |
| 4 | Novartis Ag | 266.30 Bn | 258.61 Bn | 11.24 Bn | 18.04% |
| 5 | Pfizer | 158.95 Bn | 147.25 Bn | 10.94 Bn | 39.10% |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | 56.97% |
| 7 | Revolution Medicines | 44.29 Bn | 44.29 Bn | - | - |
| 8 | Incyte | 25.27 Bn | 20.73 Bn | 1.57 Bn | 18.31% |
| 9 | United Therapeutics | 21.44 Bn | 18.78 Bn | 683.80 Mn | 43.42% |
| 10 | United Guardian | 32.67 Mn | 23.07 Mn | 1.55 Mn | 51.79% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 51.79% |
| Mar 31, 2026 | 13.12% |
| Dec 31, 2025 | -19.12% |
| Sep 30, 2025 | 11.17% |
| Jun 30, 2025 | -35.63% |
| Mar 31, 2025 | 127.33% |
| Dec 31, 2024 | -45.51% |
| Sep 30, 2024 | 6.01% |
| Jun 30, 2024 | -6.64% |
| Mar 31, 2024 | -13.35% |
| Dec 31, 2023 | 18.80% |
| Sep 30, 2023 | 86.14% |
| Jun 30, 2023 | -38.80% |
| Mar 31, 2023 | -31.29% |
| Dec 31, 2022 | -9.72% |
| Sep 30, 2022 | -9.24% |
| Jun 30, 2022 | 0.77% |
| Mar 31, 2022 | -73.84% |
| Dec 31, 2021 | 16.90% |
| Sep 30, 2021 | -4.71% |